ERBB2 and papillary renal cell carcinoma: While tumor-targeted delivery of Her2-AAV-PD1 in Her2/neu positive renal adenocarcinoma-bearing mice resulted in no significant difference in levels of anti-PD-1 in tumors compared to non-targeted delivery of scFc-Fc with AAV2 (1.9 ± 0.11 ng anti-PD-1/mg protein for Her2-AAV-PD−1 vs. 3.28 ± 1.22 ng anti-PD-1/mg protein for AAV2-PD−1), the anti-PD-1 levels were significantly decreased in liver and serum.